Are biotech’s fortunes finally changing? Is Big Science impeding actual science? And what will Medicare negotiation mean for drug prices?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. STAT’s Jason Mast joins us to discuss Jim Wilson, a pioneering scientist synonymous with the rise of gene therapy who staffers say presided over a toxic, abusive workplace. We also explain the latest news in the life sciences, including a multibillion-dollar deal, a novel approach to treating schizophrenia, and what the Senate drug pricing legislation means for the pharmaceutical industry.
Preparing for the future of mRNA in the need-for-speed era
mRNA got its spot in the limelight in the midst of a global pandemic, but it also holds great potential in moving us closer to the reality of personalized medicine. That opportunity, of course, will come with considerations for how the biopharma industry plans for the future. Hear from Linda Matthiason, Strategic Customer Lead, Nucleic Acid Therapeutics at Cytiva, who will highlight some of the unique hurdles in advancing future mRNA therapeutics. Read the article here.
No comments